Further evaluation will also be required to determine the role of the forward and reverse signalling induced by these Ephrins members in the GBM tumoral context, even if the development of a monoclonal antibody blocking Ephrin-B3/EphA4 interaction may turn as a promising approach. This evidence concerns the gene EPHA4 and glioblastoma.